The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Zantac 150 mg/10 ml Syrup

150 milligram/ 10 millilitre Syrup

GlaxoSmithKline (Ireland) LimitedPA1077/013/002

Main Information

Trade NameZantac 150 mg/10 ml Syrup
Active SubstancesRANITIDINE HYDROCHLORIDE
Strength150 milligram/ 10 millilitre
Dosage FormSyrup
Licence HolderGlaxoSmithKline (Ireland) Limited
Licence NumberPA1077/013/002

Group Information

ATC CodeA02BA H2-receptor antagonists
A02BA02 ranitidine

Status

Authorised/WithdrawnWithdrawn
Withdrawn Date15/01/2021
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Generics Information

Interchangeable List CodeIC0087-144-054
Interchangeable List DocumentPDF of Interchangeable List
« Back